secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K
Filed at:   2026-03-04T23:59:59+00:00
Accession:  0001104659-26-023467
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liminatus Pharma reduces stockholder quorum requirement from majority to one-third
--------------------------------------------------------------------------------

- Board approved bylaw amendment reducing quorum from majority to one-third of voting power.
- Amendment effective immediately upon Board adoption on February 27, 2026.
- Bylaw amendment to be submitted for stockholder ratification at next annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926023467/0001104659-26-023467-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926023467/tm267974d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-023467

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer